ArticleMethods and protocols2026
A Practical Workflow for Correcting Kit-Specific Effects in Whole-Exome Sequencing Data.
Article in Methods and protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Large-scale, multi-center projects have become common in the era of rapid technological development, but protocol standardization remains challenging. In whole-exome sequencing (WES), various exome enrichment kits exhibit variable efficiency across genomic regions, leading to systematic, non-biological batch effects, much stronger than other technical factors. We propose a workflow to minimize the effect of WES capture inconsistencies in single-nucleotide variation (SNV) data. The pipeline consists of quality control, mapping to the genome, SNV calling, joint genotyping, and imputing genotypes using reference haplotypes. SNVs are then aggregated into gene-level features measuring the burden of deleterious variants. Finally, a gene-level imputation is performed using a customized algorithm. Namely, if the detection rate of a gene is low in samples enriched with a given capture kit but high in samples enriched with other kits, missing values in the former group are imputed, as such differences are unlikely to reflect true biology. As a benchmark, we conducted a study on over a thousand breast cancer cases across 11 cohorts, using eight exome capture kits. We demonstrated that the proposed pipeline leads to a considerable decrease in the batch effect signal, potentially increasing the likelihood of finding true biological signals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.